Overview: NGS Ataxia-Telangiectasia Sequencing TestIntroduction: The NGS Ataxia-Telangiectasia Sequencing Test sequences genes to diagnose ataxia-telangiectasia, causing movement issues or infections. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected ataxia-telangiectasia (A-T).
Other Names: A-T Assay, ATM Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: A-T sequencing began in the 1990s with DNA repair disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose ataxia-telangiectasia, guides treatment, and evaluates patients with movement issues or infections.
Test Parameters: 1. Ataxia-Telangiectasia Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of movement issues, infections, or A-T symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document movement issues, infections, telangiectasia, or family history of A-T. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, A-T implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze A-T genes (e.g., ATM). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for A-T diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm A-T, guiding supportive care or cancer surveillance. Negative results may require immunoglobulin testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Immunoglobulin levels, alpha-fetoprotein, or brain MRI to confirm A-T diagnosis.
Test Limitations: Not all A-T cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN A-T Guidelines, 2023; Neurology, Gatti RA, 2022.
